The collaborative atorvastatin diabetes study: preliminary results.

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes is a major risk factor for cardiovascular disease.
• Primary prevention strategies are crucial for managing cardiovascular risk in diabetic patients.
• Statins are widely used for cholesterol management, but their role in primary prevention for certain diabetic populations requires specific investigation.

Purpose of the Study:

• To evaluate the efficacy of atorvastatin in primary prevention of cardiovascular events in patients with type 2 diabetes.
• To assess the impact of atorvastatin on cardiovascular outcomes in individuals without pre-existing vascular disease and with average or below-average cholesterol levels.

Main Methods:

• Prospective, double-blind, randomized, placebo-controlled trial (Collaborative AtoRvastatin Diabetes Study - CARDS).
• 2383 type 2 diabetic subjects aged 40-75 years randomized to 10-mg atorvastatin daily or placebo.
• Trial terminated early due to demonstrated benefit.

Main Results:

• Atorvastatin 10 mg reduced low-density lipoprotein cholesterol (LDL-C) by 40% on average.
• A 37% relative risk reduction in the primary endpoint (major cardiovascular events and stroke) was observed (p <0.001).
• Significant reductions were also seen in total mortality (27%), acute coronary events (36%), coronary revascularization (31%), and stroke (48%).

Conclusions:

• Atorvastatin 10 mg provides significant primary prevention benefits for cardiovascular events in patients with type 2 diabetes, irrespective of baseline LDL-C levels.
• The study supports the use of statins for primary cardiovascular risk reduction in this specific diabetic population.
• The observed benefits may be underestimated due to protocol allowances for statin use in the placebo group and discontinuations in the active group.